Related Experiment Video
Updated: May 26, 2026

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
Published on: March 14, 2014
Fungal infection in heart-lung transplant recipients receiving single-agent prophylaxis with itraconazole
Don Hayes1, Amanda M Ball, Heidi M Mansour
1University of Kentucky, Lexington, KY, USA. don.hayes@uky.edu
Objectives:
Heart and lung transplant recipients are at risk for invasive fungal infections. This study evaluated the affect of single-agent antifungal prophylaxis with itraconazole on the rate of fungal infections after heart or lung transplant.
Materials And Methods:
An observational, retrospective study was performed to evaluate the rate of fungal infections in heart and lung transplant recipients at the University of Kentucky Medical Center over 4.5 years who received itraconazole as a single therapy prophylaxis.
Results:
Eighty-three recipients (42 heart, 41 lung) had an overall fungal infection incidence of 16.9% (14/83), while the incidence was 11.9% for heart recipients (5/42), and 22.0% for lung recipients (9/41).
Conclusions:
Single-agent use with itraconazole in heart or lung transplant recipients did not affect the rate of fungal infection as compared with previous reports. The incidence of fungal infection increased significantly within 3 months after escalation of immunosuppressant for treatment of acute rejection.
Insights
Single-agent antifungal prophylaxis with itraconazole did not alter fungal infection rates in heart and lung transplant patients. Infections increased with immunosuppression escalation for acute rejection.
Area of Science:
- Transplant medicine
- Infectious diseases
- Pharmacology
Background:
- Heart and lung transplant recipients face a high risk of invasive fungal infections.
- Antifungal prophylaxis is crucial in managing post-transplant complications.
Purpose of the Study:
- To evaluate the impact of single-agent itraconazole prophylaxis on fungal infection rates in heart and lung transplant recipients.
- To assess the efficacy of itraconazole in preventing invasive fungal infections post-transplant.
Main Methods:
- Observational, retrospective study design.
- Evaluation of 4.5 years of data from heart and lung transplant recipients at the University of Kentucky Medical Center.
- Analysis of fungal infection incidence in patients receiving itraconazole prophylaxis.
Main Results:
- Overall fungal infection incidence was 16.9% (14/83) across both groups.
- Heart transplant recipients had an 11.9% incidence (5/42), while lung recipients had a 22.0% incidence (9/41).
- No significant change in fungal infection rates was observed compared to historical data.
Conclusions:
- Single-agent itraconazole prophylaxis did not significantly affect fungal infection rates in heart or lung transplant recipients.
- A notable increase in fungal infections occurred within 3 months of escalating immunosuppression for acute rejection.
- Further strategies may be needed to manage fungal infections in this vulnerable population.
Related Concept Videos
Antifungal Agents
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Endocarditis III: Medical Management
Endocarditis I: Introduction
Endocarditis IV: Nursing Management
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
